An­oth­er BioCryst Fac­tor D in­hibitor hits clin­i­cal de­lay two months af­ter first one dis­con­tin­ued

BioCryst’s most ad­vanced ex­per­i­men­tal drug in its cur­rent pipeline has hit a snag, the com­pa­ny said Tues­day as part of its Q4 re­port.

BCX10013, an oral Fac­tor D in­hibitor for the treat­ment of com­ple­ment-me­di­at­ed dis­eases, is fac­ing de­lays in a clin­i­cal pro­gram be­cause of “re­cent dose-re­lat­ed ob­ser­va­tions” in a non­clin­i­cal study, ac­cord­ing to BioCryst. The com­pa­ny didn’t say much more than that.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER